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Research article

Glypican-1 modulates the angiogenic
and metastatic potential of human
and mouse cancer cells
Takuma Aikawa,1 Chery A. Whipple,1 Martha E. Lopez,2 Jason Gunn,1 Alison Young,1
Arthur D. Lander,2 and Murray Korc1
1Department of Medicine, Department of Pharmacology and Toxicology, and the Norris Cotton Comprehensive Cancer Center,
Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Hanover, New Hampshire, USA. 2Department of Developmental and Cell Biology,
University of California, Irvine, Irvine, California, USA.

Cells isolated from many types of human cancers express heparin-binding growth factors (HBGFs) that drive
tumor growth, metastasis, and angiogenesis. The heparan sulfate proteoglycan glypican-1 (GPC1) is a coreceptor for HBGFs. Here we show that both cancer cell–derived and host-derived GPC1 are crucial for efficient
growth, metastasis, and angiogenesis of human and mouse cancer cells. Thus downregulation of GPC1 in the
human pancreatic cancer cell line PANC-1, using antisense approaches, resulted in prolonged doubling times
and decreased anchorage-independent growth in vitro as well as attenuated tumor growth, angiogenesis, and
metastasis when these cells were transplanted into athymic mice. Moreover, athymic mice that lacked GPC1
exhibited decreased tumor angiogenesis and metastasis following intrapancreatic implantation with either
PANC-1 or T3M4 human pancreatic cancer cells and fewer pulmonary metastases following intravenous injection of murine B16-F10 melanoma cells. In addition, hepatic endothelial cells isolated from these mice exhibited an attenuated mitogenic response to VEGF-A. These data indicate that cancer cell– and host-derived GPC1
are crucial for full mitogenic, angiogenic, and metastatic potential of cancer cells. Thus targeting GPC1 might
provide new avenues for cancer therapy and for the prevention of cancer metastasis.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in the United States and is responsible
for over 20% of deaths due to gastrointestinal malignancies in
other industrialized countries (1). Although recent diagnostic
and therapeutic advances have slightly prolonged the survival
of patients with PDAC, the overall prognosis of these patients
is still extremely poor (1, 2). With some exceptions, long-term
survival is often limited to patients who have surgery at an early
stage of the disease. However, all too often the diagnosis of PDAC
is established when metastases have already occurred, excluding
these patients from attempts at curative resection (1, 2). There
is an urgent need, therefore, for an improved understanding of
the molecular mechanisms that contribute to pancreatic tumor
growth and metastasis.
Proteoglycans are ubiquitous macromolecules that are found on
cell surfaces, in the extracellular matrix, and in connective tissues
and that have been implicated in promoting tumor growth (3–5).
Proteoglycans consist of specific core proteins to which a variable
number of polysaccharide chains are covalently attached. These
polysaccharide chains, or glycosaminoglycans (GAGs), are variable
in type and size and typically consist of disaccharide repeats of
d-glucuronic or l-iduronic acid and either N-acetylglucosamine
or N-acetylgalactosamine (3–6). GAGs have a high charge density
Nonstandard abbreviations used: GAS, GPC1 antisense–transfected; GPC1, glypican-1; GPI, glycosylphosphatidylinositol; HB-EGF, heparin-binding EGF-like growth
factor; HBGF, heparin-binding growth factor; HS, heparan sulfate; HSPG, HS proteoglycan; MEF, murine embryonic fibroblast; PCNA, proliferating cell nuclear antigen;
PDAC, pancreatic ductal adenocarcinoma.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 118:89–99 (2008). doi:10.1172/JCI32412.
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and exhibit marked diversity due to variations in the disaccharides
and sites of sulfation (7). In addition to heparin and heparan sulfate (HS), GAGs may consist of chondroitin or dermatan sulfates,
keratan sulfate, or hyaluronan. The aberrant expression of a number of these HS proteoglycans (HSPGs) has been implicated in a
variety of human malignancies (5). In this regard, the roles of 2
types of HSPGs, the glypicans and syndecans, have been examined
in great detail because both of these families of polypeptides carry
the majority of the HS on mammalian cells.
There are 6 glypicans, which are attached to the plasma membrane via glycosylphosphatidylinositol (GPI) anchors, and 4 syndecans, which are transmembrane proteins, all encoded by separate
genes (3–9). Glypicans and syndecans participate in the regulation
of cell-cell interactions and the interactions between heparin-binding growth factors (HBGFs) and their cognate high-affinity receptors (5–6, 8–10). Among the 6 members of the glypican family, only
glypican-1 (GPC1) is overexpressed in PDAC, and attenuation of
GPC1 expression dampens the mitogenic responses to HBGFs and
slows pancreatic tumor growth in vivo (11, 12).
In the present study we compare the consequences of GPC1
suppression in the cancer cells and in the mouse host. Decreased
GPC1 expression in PANC-1 cells was associated with a significant
decrease in cell doubling time and attenuated anchorage-independent growth. In athymic mice, the same cells exhibited decreased
subcutaneous and intrapancreatic tumor growth and attenuated
angiogenesis and metastasis by comparison with sham-transfected
PANC-1 cells. Moreover, PANC-1– and T3M4-derived intrapancreatic tumors exhibited attenuated angiogenesis and metastasis in
athymic GPC1-null mice when compared with tumors in WT athymic mice. The GPC1-null mice also developed fewer pulmonary
metastases following intravenous injection of murine B16-F10
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Figure 1
Effects of GPC1 antisense expression on GPC1 protein levels. (A)
Effects of enzymatic treatment on immunoblotting. Sham-transfected cells and GPC1 antisense–expressing cells (clone GAS6) were
incubated in the absence or presence of the indicated enzymes and
subjected to immunoblotting using affinity-purified rabbit anti-GPC1
antibody as reported in Methods. (B) Total cell lysates from shamtransfected and from both antisense-expressing clones as well as the
corresponding conditioned media were incubated with heparitinase
and chondroitinase ABC and subjected to immunoblotting as described
above. Membranes from cell lysates were reprobed with an anti-ERK2
antibody to confirm equivalent loading of lanes. Each panel is representative of 2 distinct experiments.

melanoma cells. Thus both cancer cell– and host-derived GPC1
are important for tumor growth, angiogenesis, and metastasis.
Results
Effects of GPC1 levels on the in vitro growth properties of PANC-1 cells.
To assess cellular GPC1 protein levels, immunoblotting with an
anti-GPC1 antibody was performed using total cell lysates from
sham-transfected and GPC1 antisense–transfected (GAS) clones
of PANC-1 cells that were incubated in the absence or presence
of deglycanating enzymes. Due to the poor binding of glycanated
GPC1 to blotting membranes, it either fails to appear on immunoblots or appears as a series of faint bands and broad high-molecular-weight smears (11). As expected, the antibody detected the
presence of multiple GPC1 bands in the absence of enzymatic treatment (Figure 1A). By contrast, following heparitinase
digestion of the HSs, a broad major band was readily visible in sham-transfected cells (Figure 1A). The intensity
of the band was increased slightly when the digestion
was performed in the presence of both heparitinase and
chondroitinase ABC, an enzyme that removes chondroitin sulfates. Thus the majority of GPC1 molecules contained only small amounts of chondroitin sulfate (13),
and the anti-GPC1 antibody recognized human GPC1
in a highly specific manner. As was the case with whole

cell lysates, the GAS6 clone released smaller amounts of GPC1 into
the medium than the GAS7 clone, and both clones released less
GPC1 than sham-transfected cells (Figure 1B).
PANC-1 cells express many growth factors, including several
HBGFs such as heparin-binding EGF-like growth factor (HBEGF) and amphiregulin (14, 15). Two types of experiments were
performed to determine whether GPC1 levels facilitated autocrine
growth stimulation in these cells. First, the effects of altering GPC1
expression on cell doubling times were examined. Sham-transfected
cells exhibited a doubling time of 22.5 hours. By contrast, the GAS
clones GAS6 and GAS7 displayed significantly longer doubling
times (33.0 h and 28.6 h, respectively). Second, the consequences of
lowering GPC1 expression on anchorage-independent growth were
assessed by monitoring colony formation in soft agar (Figure 2A).

Figure 2
Cell growth assays. (A) Effects of GPC1 levels on basal
anchorage-independent growth. Sham-transfected PANC-1
cells and GPC1 antisense–expressing clones were seeded
in 6-well plates (3,000/well) in complete medium containing 0.3% agar. After 14 days, colonies having more than
20 cells were counted. Data indicate the mean ± SEM of
triplicate determinations from 3 experiments. #P < 0.01
compared with sham-transfected cells. (B) Effects of GPC1
levels on growth factor–stimulated anchorage-independent
growth. Sham-transfected (filled symbols) and GPC1 antisense mRNA–expressing PANC-1 cells (open symbols)
were seeded in 6-well plates (3,000/well) in serum-free
medium containing 0.3% agar. Serum-free medium containing 1 nM HB-EGF, FGF2, EGF, or IGF-1 was added every
4 days. After 14 days, colonies having more than 20 cells
were counted. Data are expressed as percentage change
from the respective controls (mean ± SEM) of 3 determinations per experiment from 3 separate experiments.
*P < 0.05 and **P < 0.03 compared with control.
90

The Journal of Clinical Investigation

http://www.jci.org

Volume 118

Number 1

January 2008

research article
Figure 3
Effects of GPC1 levels on tumor growth. (A) Representative tumors.
GAS6 cells consistently formed smaller tumors than sham-transfected
cells. The mice bearing GAS tumors appeared healthy. By contrast,
the mice bearing tumors from sham-transfected cells had to be terminated due to their cachectic appearance, tumor size, and tendency of
the tumors to develop surface ulcerations. (B) Tumor growth curves.
Exponentially growing (2 × 106) sham-transfected PANC-1 cells (filled
diamonds) and GAS7 (open triangles) and GAS6 (open squares) cells
were injected subcutaneously in athymic mice, and tumor growth was
measured weekly. Tumor volume was determined by the equation: volume = (l × h × w) × π /4, where l is length, h is height, and w is width of
the tumor. Data are mean ± SEM from 9 tumors for sham-transfected
PANC-1 cells and for each of the 2 GAS clones.

Thus under similar incubation conditions, sham-transfected cells
formed 591 ± 5 colonies, whereas GAS6 and GAS7 clones formed
273 ± 14 and 392 ± 6 colonies, respectively. To assess whether GPC1
levels modulated growth factor responsiveness in an anchorageindependent environment, the effects of 2 HBGFs (FGF-2 and HBEGF) and 2 non-HBGFs (EGF and IGF-I) on cell growth in soft agar
were determined (Figure 2B). FGF-2 and HB-EGF increased colony
formation of sham-transfected PANC-1 cells, and this effect was
markedly attenuated in GAS clones. In contrast, the growth stimulatory action of EGF and IGF-I were similar in both groups of cells
(Figure 2B). Taken together, these observations suggest that cancer cell–derived HBGFs require the presence of GPC1 for efficient
autocrine-paracrine growth stimulation.
Effects of GPC1 levels on the in vivo growth properties of PANC-1 cells.
To compare the tumorigenicity of GAS PANC-1 cells with shamtransfected cells, 2 × 106 sham-transfected cells, GAS6, or GAS7
cells were injected subcutaneously at 1 site per athymic mouse.
GAS6 cells formed consistently smaller tumors than GAS7 cells
(Figure 3A), and both GAS6 and GAS7 cells formed smaller
tumors than sham-transfected cells (Figure 3B). At 8 weeks following tumor injection, there was a 74% decrease in growth in the

9 GAS6-derived tumors and a 48% decrease in the 9 GAS7-derived
tumors, by comparison with tumors from sham-transfected
cells. Due to the need for multiple comparisons at multiple time
points, statistical significance was determined using ANOVA,
followed by Tukey’s honest significant difference (HSD) test of
the comparisons that were deemed significant by ANOVA, with
P < 0.05 taken as statistically significant. This analysis indicated
that GAS6-derived tumors were significantly smaller (P < 0.05)
than the tumors derived from sham-transfected cells at all
measured time points. By contrast, GAS7-derived tumors were
only significantly different at 2 weeks after cancer cell injection
(P < 0.05). However, analysis of the combined data from all 18
GAS tumors at the 8-week time point revealed a significant
decrease in tumor volumes at 8 weeks (P < 0.03) when compared
with the 9 sham-derived tumors.
Immunoblotting of whole tumor lysates (Figure 4A), followed by
densitometric analysis (Figure 4B), was carried out next in order to
compare GPC1 protein levels in the tumors from all 3 groups. This
analysis revealed that GPC1 protein levels were decreased by 48%
(P < 0.005) and 34% (P = 0.06) in the tumors derived from GAS6

Figure 4
GPC1 expression in tumor xenografts. (A) Immunoblotting. Tumors
from sham-transfected and GAS PANC-1 cells (GAS6 and GAS7)
were homogenized and incubated with control buffer, heparitinase, or
heparitinase and chondroitinase ABC (Ch-ABC). Protein lysates were
subjected to immunoblotting using affinity-purified rabbit anti-GPC1
antibody as reported in Methods. Membranes from cell lysates were
reprobed with an anti-ERK2 antibody to confirm equivalent loading
of lanes. (B) Densitometric analysis. Frozen lysates for immunoblotting from 6 sham, 5 GAS6, and 4 GAS7 tumors were subjected to
densitometry. *P < 0.005 compared with sham.
The Journal of Clinical Investigation
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Figure 5
Effects of GPC1 levels on CD31 immunoreactivity in subcutaneous
tumors. (A) Analysis of vessel number. Morphometric analysis of vessel number was performed as described in Methods, using an antiCD31 antibody. Data are based on immunohistochemical staining of
10 tumors from sham-transfected PANC-1 cells, 7 tumors from GAS6
cells, and 10 tumors from GAS7 cells. (B) Analysis of vessel area.
Morphometric analysis on the same tumors was carried out based
on the area occupied by the vessels. Data are the means ± SEM.
*P < 0.05 and **P < 0.01 compared with sham.

and GAS7 clones, respectively, by comparison with tumors arising
from sham-transfected cells. Thus GPC1 levels in tumors derived
from antisense-expressing clones remained low throughout the in
vivo study, but this decrease did not achieve statistical significance
in the GAS7-derived tumors, due in part to the somewhat greater
variability in GPC1 levels observed in these tumors.
Tumor vessel counts, cell apoptosis, and proliferation. To assess the
effects of decreased endogenous GPC1 levels on tumor angiogenesis, immunohistochemical staining of tumors that were removed
8 weeks following cancer cell injection was performed with antiCD31 antibodies. There was a readily visible decrease in the number of CD31-positive cells in tumors formed by GAS6 and GAS7
clones by comparison with tumors formed by sham-transfected
cells (data not shown). Morphometric analysis of vessel number
revealed a 38% (P < 0.05) and a 42% (P < 0.05) decrease in microvessel densities in the tumors formed by the 2 clones by comparison
with the tumors from sham-transfected cells (Figure 5A). Similar
results were observed on the basis of the area occupied by CD31positive cells (Figure 5B), with GAS6 and GAS7 clones exhibiting
decreases of 36% (P < 0.001) and 41% (P < 0.001), respectively. Cell
proliferation, as determined by monitoring proliferating cell nuclear antigen (PCNA) immunoreactivity, was significantly decreased
in GAS6- (P < 0.005) but not GAS7-derived tumors (Figure 6). By
contrast, immunohistochemical analysis for apoptosis using the
TUNEL assay failed to reveal a significant difference between the
3 groups of tumors (data not shown), indicating that the observed
differences in tumor size were not due to any differences in susceptibility to apoptosis.
Effect of GPC1 levels on MAPK activation in the tumors. Inasmuch
as many HBGFs frequently exert their mitogenic effects through

activation of the MAPK pathway, it was of interest to determine
whether MAPK activation was attenuated in the tumors that
arose from GPC1 antisense– expressing PANC-1 cells. Accordingly, immunoblotting with anti–phospho-MAPK antibody was
performed next (Figure 7). The levels of both forms of phosphoMAPK (phospho-ERK1 and -ERK2) were significantly decreased
in tumors from both GAS6 (P < 0.05) and GAS7 clones (P < 0.05)
by comparison with the corresponding levels in tumors derived
from sham-transfected cells. Thus the ability to activate MAPK
was significantly altered even in tumors whose GPC1 levels were
only modestly decreased.
Effect of GPC1 levels on the expression of Tie2 receptor and ligands.
Angiopoietin-1 and -2 are ligands that bind the Tie2 tyrosine
kinase receptor, which is most often expressed by endothelial
cells (16) but is also expressed in some cancer cells such as breast
cancer and glioma cells (17, 18). While angiopoietin-1 generally
acts as an agonist of Tie2 and angiopoietin-2 generally acts as an
antagonist (16, 19), at high ligand concentrations angiopoietin-2
can also act as an agonist (20), and both ligands have been implicated in tumor angiogenesis because of their survival-promoting effects on endothelial cells and because they stimulate the
sprouting of new blood vessels in the presence of high VEGF-A
levels (20–24). VEGF-A, whose expression is increased in PDAC
(25), is known to upregulate angiopoietin expression (26), and
VEGF-A actions as well as angiopoietin actions require the presence of HSPGs (27). It was of interest, therefore, to assess the
expression of angiopoietins, Tie2, and VEGF-A in sham-transfected and GAS6 cells as well as in the tumors derived from these
cells. By quantitative real-time PCR, angiopoietin-1 levels were
increased in cultured GAS6 cells when compared with shamtransfected cells, whereas angiopoietin-2 and Tie2 mRNA levels
were significantly decreased in these cells and VEGF-A mRNA
levels were not altered (Figure 8). By contrast, the levels of all
4 mRNA moieties were significantly decreased in tumors from

Figure 6
Effects of GPC1 levels on PCNA immunoreactivity in subcutaneous
tumors. Morphometric analysis of PCNA immunoreactivity was performed as described in Methods, using 10 tumors from sham-transfected PANC-1 cells, 6 tumors from GAS6 cells, and 9 tumors from
GAS7 cells. Data are means ± SEM. *P < 0.01 compared with sham.
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Figure 7
Effects of GPC1 levels on phospho-MAPK in subcutaneous tumors.
(A) Immunoblotting for active ERK1/2. Lysates from 10 tumors from
sham-transfected PANC-1 cells, 8 tumors from GAS6 cells, and 6
tumors from GAS7 cells were subjected to immunoblotting with anti–
phospho-MAPK antibody as described in Methods. (B) Densitometric analysis. Band intensities for active ERK1 and active ERK2 were
normalized to total ERK2 (loading control). Data are means ± SEM.
*P < 0.05 compared with sham.

GAS6 and GAS7 cells by comparison with tumors from shamtransfected PANC-1 cells (Figure 9).
To determine whether angiopoietin-1 and -2 and Tie2 were
expressed in the cancer cells within the tumor mass, immuno
staining was next carried out in the tumors from sham-transfected cells. Angiopoietin-1 and -2 as well as Tie2 were present in a
heterogeneous pattern within the cancer cells (Figure 10) and in
the endothelial cells within the tumor mass. Both angiopoietins
exhibited cytoplasmic distribution in the cancer cells, whereas
Tie2 immunoreactivity was distinctly membranous.
Effect of GPC1 levels on tumor growth and metastasis in an orthotopic
model. To determine whether GPC1 levels in the cancer cells dictated the extent of tumor metastasis, 2 × 106 sham-transfected
or GAS6 and GAS7 cells were injected into the pancreas of nude
mice. Six weeks after tumor inoculation, the intrapancreatic
tumors of sham-transfected PANC-1 cells were significantly larger
than those arising from either GAS6 or GAS7 clones (Table 1).
All 10 tumors arising from sham-transfected cells were associated
with local and/or mesenteric node metastasis, and 2 mice exhibited peritoneal dissemination and ascites (Table 1). By contrast,
only 3 of 20 tumors arising from GAS cells yielded lymph node
metastasis, and none exhibited mesenteric involvement, peritoneal spread, or ascites (Table 1).
Tumor growth and metastasis in a GPC1-knockout model. To assess
the role of endogenous GPC1 on tumor growth, sham-transfected
PANC-1 cells were injected into the pancreas of both WT nude mice
and GPC1-null mice on the same athymic background (Table 2).
By 10 weeks after tumor inoculation, all 7 WT mice appeared ill,
leading to termination of the experiment, and all harbored intrapancreatic tumors, which formed extensive metastases. The eighth
mouse in this group died of unknown causes 2 weeks following
cancer cell injection and was therefore not evaluated. By contrast,
only 5 of 8 GPC1–/– mice formed tumors, and the mean volume of
these 5 tumors was significantly smaller than the mean volume of
the 7 tumors in the WT mice (Table 2). The tumors in the GPC1–/–
group also exhibited attenuated angiogenesis (52% decrease in

microvessel density; P < 0.0005), and none of these tumors formed
metastases (Table 2). Moreover, all the mice in this group appeared
healthy at the end of the experiment.
To confirm that host GPC1 was not uniquely important for
PANC-1 cells, we next compared the growth of T3M4 pancreatic
cancer cells in WT and GPC1-null nude mice (Table 3). T3M4 cells
grow more rapidly in vivo than PANC-1 cells. Therefore, only 2 × 105
T3M4 cells were injected into each pancreas, and the experiment
was terminated 4 weeks later due to the concern that rapid tumor
growth would be unpredictably lethal. Although at this time point
tumor volumes were similar in both groups, the WT mice exhibited multiple metastatic lesions (Figure 11), whereas the GPC1–/–
were devoid of metastases (Table 3). Moreover, as in the case of the
tumors derived from PANC-1 cells, angiogenesis was decreased by
52% (P < 0.04) in the T3M4-derived tumors in GPC1–/– mice by
comparison with tumors in the WT mice (Table 3).
To determine whether GPC1-null mice exhibited an attenuated capacity to form metastases from nonpancreatic cancer cells,
the murine B16-F10 pulmonary metastasis model was examined
next (Figure 12). By comparison with WT mice, the melanoma
cells formed 62% fewer pulmonary metastases in the GPC1-null
mice (P < 0.006).
In vitro effects of growth factors on endothelial cell proliferation. To
determine whether endothelial cells isolated from GPC1–/– mice
exhibit normal proliferative responses, proliferation assays were
performed next, using endothelial cells isolated from the liver of
WT and GPC1-null mice (Figure 13). VEGF-A (1 nM) caused a significantly greater increase in cell proliferation in the WT-derived
endothelial cells by comparison with the GPC1–/– cells. To confirm
the selective loss of GPC1 in endothelial cells and murine embryonic fibroblasts (MEFs) isolated from GPC1-null mice, quantitative PCR was performed next, using RNA prepared from the
respective cells. As expected, both cell types, when isolated from
GPC1-null mice, exhibited complete loss of the GPC1 mRNA transcript, whereas the levels of GPC2–GPC6 and syndecans 1–4 were
similar in the endothelial cells and MEFs isolated from WT and
GPC1-null mice (data not shown).

Figure 8
Effects of GPC1 levels on the expression of proangiogenic factors
in PANC-1 cells in culture. RNA extracted from sham-transfected
PANC-1 cells and GAS6 cells was subjected to real-time quantitative
PCR. Relative expression levels were determined in triplicate. Data are
means ± SEM from 3 different experiments. *P < 0.01 compared with
the corresponding sham.
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Figure 9
Effects of GPC1 levels on the expression of proangiogenic factors
in PANC-1–derived subcutaneous tumors. RNA extracted from
tumors derived from sham-transfected PANC-1 cells and 2 GPC1
antisense PANC-1 clones was subjected to real-time quantitative
PCR. Relative expression levels were determined in triplicate. Data
are the means ± SEM from 6 sham and 4 GAS6 and 3 GAS7 tumors.
*P < 0.01 when compared with the corresponding sham.

Discussion
PDAC is characterized by multiple genetic alterations, including a high frequency of mutations in the K-ras oncogene, the
p53 and Smad4 tumor suppressor genes, and the p16 cell cycle
inhibitory gene (28). In addition, there is overexpression of multiple growth factors and their cognate tyrosine kinase receptors,
which act to promote mitogenesis, cancer spread and invasiveness, and angiogenesis (29). Many of these growth factors,
including FGFs, HB-EGF, amphiregulin, hepatocyte growth factor, the high-molecular-weight forms of VEGF-A and TGF-βs
either are HBGFs and/or interact with HSPGs. Oftentimes, these
interactions lead to enhanced binding with the respective highaffinity receptors (30, 31).
We previously reported that the expression of the HSPG GPC1
is upregulated in PDAC but that other members of the glypican
family are not overexpressed in this malignancy (11). We also
demonstrated that GPC1 exerts a promitogenic role in pancreatic
cancer cells and showed that treatment with PIPLC, which cleaves
the GPI anchor of GPC1, abrogates the mitogenic responses of
PANC-1 and COLO-357 pancreatic cancer cells to FGF-2 and HBEGF, 2 HBGFs that are commonly overexpressed in PDAC (11).
Furthermore, we determined that expression of a form of GPC1
engineered to possess a transmembrane domain instead of a GPI
anchor conferred resistance to the inhibitory effects of PIPLC on
growth factor responsiveness and that transfection of a GPC1
antisense construct attenuated the mitogenic response to FGF-2
and HB-EGF (11). In contrast, neither PIPLC treatment nor GPC1
antisense expression altered the response of the cancer cells to the
non-HBGFs EGF and IGF-1. Together these observations suggested that GPC1 may play a crucial role in enhancing the mitogenic
actions of HBGFs in pancreatic cancer cells.
In the present study, suppression of GPC1 expression in PANC-1
cells led to markedly prolonged doubling times, decreased basal
anchorage-independent growth, and a failure of exogenously
added HB-EGF and FGF-2 to enhance anchorage-independent

growth. However, in the subcutaneous athymic mouse model, only
GAS6-derived tumors exhibited attenuated tumor growth and a
significant decrease in cancer cell proliferation, whereas the corresponding values in GAS7-derived tumors did not achieve statistical
significance. By contrast, GPC1 suppression was associated with
attenuated MAPK activation in both GAS6- and GAS7-derived
tumors and with a marked decrease in the microvessel density.
Taken together, these observations indicate that GPC1 allows for
efficient autocrine and paracrine activation of growth-promoting
pathways in pancreatic cancer cells, that in the face of a sufficient
decrease in GPC1 the in vivo levels of non–HBGFs such as EGF
and IGF-1 are not adequate for overcoming the decrease in HBGFdependent mitogenic signaling, and that both MAPK activation
and tumor angiogenesis are exquisitely dependent on the presence
of GPC1, perhaps because sustained MAPK activation by HBGFs
is GPC1 dependent (32).
In addition to a decrease in microvessel density, the tumors
from the GPC1 antisense–expressing cells exhibited a significant
decrease in Tie2, angiopoietin-1, angiopoietin-2, and VEGF-A
mRNA levels (Figure 9). In the case of Tie2 and angiopoietin-2, this
decrease was in part due to a cell-autonomous attenuation in their
expression in the GPC1 antisense–expressing GAS6 cells in culture
(Figure 8). However, angiopoietin-1 mRNA levels were increased in
GAS6 cells that were in culture, underscoring the well-recognized
divergence in the regulation of angiopoietin-1 expression from
that of angiopoietin-2 (33). By contrast, angiopoietin-1 expression
was decreased in the tumors, indicating that in vivo environment
pathways that upregulate angiopoietin-1 are highly dependent on
the presence of GPC1. Inasmuch as quantitative PCR analysis was
performed using primers for human sequences of these mRNA
moieties, these measurements most likely reflected expression in
the cancer cells, which was confirmed by immunostaining.

Figure 10
Angiopoietin and Tie2 immunohistochemistry. Immunohistochemical
staining for angiopoietin-1, angiopoietin-2, and Tie2 was performed
as described in Methods. (A) Angiopoietin-1; (B) angiopoietin-2; (C)
Tie2; (D) control staining in the absence of a primary antibody. Original
magnification, ×100 (A and D); ×200 (B and C).
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Figure 11
Comparison of metastases in WT and GPC1-null mice. PANC-1 (A and
B) and T3M4 (C and D) human pancreatic cancer cells were injected
into the pancreas of WT (A and C) and GPC1-null (B and D) mice, as
described in the legends to Table 2 (PANC-1) and Table 3 (T3M4).
Metastatic lesions were visible in the mesentery of WT mice, but not
in GPC1-null mice.

Four mechanisms may explain the observed decrease in tumor
angiogenesis (Figure 14). First, a decrease in levels of GPC1 in the
cancer cells leads to decreased in vivo expression of VEGF-A and
angiopoietin-1 and -2, which are necessary for an efficient proangiogenic milieu within the tumor mass. Second, GPC1 on the
surface of the cancer cells can act in trans to promote angiogenesis
(34). Thus when these cells express low levels of GPC1, there is an
attenuation in the actions of proangiogenic HPGFs (35, 36) on the
tumor endothelial cells adjacent to the cancer cells. Third, GPC1
is readily shed by pancreatic cancer cells (11). Therefore, it is also
possible that decreased shedding of GPC1, as observed with the
GAS cells, acts to impede tumor angiogenesis. Fourth, GPC1 produced by fibroblasts in the tumor microenvironment (11) and by
endothelial cells (37) is necessary for efficient tumor angiogenesis,
as evidenced by the present findings in GPC1-null mice. The importance of host endothelial cell HSs in tumor angiogenesis was demonstrated in a recent study in which mice carrying an endothelial
targeted deletion of N-acetylgluocsamine N-deacetylase/N-sulfotransferase (Ndst1) exhibited decreased N-sulfation of glusoamine
residues and, consequently, attenuated tumor angiogenesis (27).
Inasmuch as the Ndst1 deletion was restricted to endothelial cells,
this study underscores the cell-autonomous effects of HSs with
respect to tumor angiogenesis.
The tumor microenvironment is of crucial importance for
pancreatic cancer growth and metastasis, as evidenced by the
fact that the subcutaneous injection of pancreatic cancer cells in
athymic mice does not yield metastases, whereas their intrapancreatic injection produces metastatic lesions. Using this orthotopic model, we determined that both GAS6 and GAS7 cells
formed significantly smaller tumors and yielded dramatically
fewer metastatic lesions than sham-transfected cells (Table 1).
These observations indicate that cancer cell–derived GPC1 is
important for intrapancreatic tumor growth and suggest that
GPC1 also contributes to the metastatic potential of pancreatic cancer cells. Metastasis was also markedly decreased in
GPC1–/– mice, using either PANC-1 (Table 2) or T3M4 (Table 3)
cells. The attenuated metastasis observed with T3M4-derived
tumors was not due to decreased intrapancreatic growth of
these tumors, indicating that host-derived GPC1 favors the
metastatic propensity of pancreatic cancer cells independently
of tumor size. Moreover, tumors from both cell types exhibited
a marked decrease in angiogenesis, indicating that host-derived
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GPC1 is also important for tumor angiogenesis within the pancreatic microenvironment.
We believe our findings are the first to demonstrate that GPC1
modulates the metastatic potential of pancreatic cancer cells.
Moreover, the GPC1 effect was not limited to such cells, inasmuch
as murine B16-F10 melanoma cells formed fewer pulmonary
metastases in the GPC1–/– mice. Several mechanisms may explain
these observations. First, decreased GPC1 levels may attenuate
metastasis by interfering with tumor angiogenesis. For example,
the VEGFR tyrosine kinase inhibitor PTK 787 (38) and the chimeric protein VEGF Trap (39), in addition to suppressing angiogenesis, markedly attenuate the ability of pancreatic cancer cells
to metastasize. Second, low GPC1 levels may interfere with GPC1dependent regulatory effects on syndecan-1 shedding, resulting in a microenvironment that is not receptive to metastatic
growth (32, 40–42). Third, GPC1 in the tumor microenvironment
enhances the storage of growth factors, promoting both their stability and their ability to act as morphogens (43, 44). Thus low
levels of GPC1 may decrease the availability of stored growth factors. Fourth, angiopoietin-2 promotes breast cancer invasion and
metastasis through an α5β1 integrin–mediated mechanism (45),
whereas Tie2 expression in gliomas enhances tumor progression
due to aberrant autocrine activation through angiopoietin-1–
and integrin β1–dependent pathways (18). It is therefore possible
that the presence of Tie2 on the surface of pancreatic cancer cells
(Figure 10C) and the abundance of integrins in PDAC (46) promotes pancreatic cancer cell metastasis and that this metastatic
pathway is attenuated in the absence of GPC1. In view of the
importance of angiogenic and metastatic processes in PDAC (34)
and the recognized contributions of tumor angiogenesis to the
metastatic process (47), taken together, the present findings suggest that targeting GPC1 may ultimately yield novel therapeutic
options in the treatment of PDAC and its metastatic lesions.
Table 1
Effects of suppressing cancer cell GPC1 on tumor metastasis
Parameter

Sham

Primary tumor volume (mm3)
823 ± 89
Mice with lymph node metastasis
10
Total local lymph nodes
31
Total mesenteric region nodes
23
Mice with peritoneal
2
dissemination/ascites

GAS6

GAS7

567 ± 55A 492 ± 59B
2C
1C
3
1
0
0
0
0

Sham-transfected or GAS PANC-1 cells (2 × 106/site) were injected into
the pancreas of nude mice, using 28-gauge needles. Six weeks later,
the volumes of the intrapancreatic tumors and the extent of metastatic
involvement were determined. Data are means ± SEM from 10 mice per
group. AP < 0.03, BP < 0.01, and CP < 0.001 compared with control. Statistical analysis was not carried out with respect to local and mesenteric
lymph node disease or peritoneal involvement.
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Table 2
Effects of host-derived GPC1 on PANC-1 metastasis
Mouse
Mice with tumor
Tumor volume (mm3)
Lymph node metastasis (no.)
Liver metastasis (no.)
Spleen metastasis (no.)
Microvessel density (% area)

WT

GPC1–/–

7/7
1,983 ± 307
319
4
1
5.8 ± 0.5

5/8
1,113 ± 356A
0
0
0
2.8 ± 0.5B

Sham-transfected PANC-1 cells (2 × 106/site) were injected into the
pancreas of WT nude and GPC1-null nude mice, using 28-gauge
needles. Ten weeks later, the volumes of the intrapancreatic tumors
and the extent of metastatic involvement were determined. Tumor volumes are means ± SEM of measurements from 7 WT mice (1 mouse
in this group was found dead 2 weeks after cancer cell injection) and 5
GPC1-null mice (3 mice in this group did not develop any grossly visible tumor during the 10-week period). Values for microvessel density
were calculated as described in Methods. AP < 0.05 and BP < 0.0005
compared with WT. Statistical analysis was not carried out with respect
to lymph node involvement.

Methods
Materials. The following materials were purchased from the following
companies: DMEM, RPMI 1640, and trypsin-EDTA from Mediatech Inc.;
FBS from Omega Scientific Inc.; G418 from GIBCO Laboratories; Noble
agar from Difco Laboratories; recombinant human EGF from Chemicon;
Heparitinase and Chondroitinase ABC Protease Free from Seikagaku Corporation; One Solution reagent and anti–phospho-MAPK antibody from
Promega; Immobilon-P PVDF membranes from Millipore Corp.; RNeasy
Mini Kit from Qiagen; phosphatidylinositol-specific phospholipase C
(PI-PLC) from Molecular Probes; magnetic dynabeads from Dynal Biotech from Invitrogen; SulfoLink Coupling Gel from Pierce Biotechnology;
anti–ERK-2 antibody, anti–angiopoietin-1 and -2 antibodies, and anti-Tie2
antibody from Santa Cruz Biotechnology Inc.; anti-CD31 rat anti-mouse
monoclonal antibody (catalog no. 553370) and anti-VE cadherin antibody
from Pharmingen; anti-PCNA monoclonal antibody from Novocastra;
Antigen Unmasking Solution from Vector Laboratories; ApopTag in situ
apoptosis detection kit from Chemicon; oligonucleotide primers from
Applied Biosystems; PANC-1 human pancreatic cancer cells and COS-7
cells from American Type Culture Collection. Murine B16-F10 melanoma
cells were a gift from Mary Jo Turk (Dartmouth Medical School, Hanover,
New Hampshire, USA) and T3M4 human pancreatic carcinoma cells were a
gift from R.S. Metzger at Duke University (Durham, North Carolina, USA).
Athymic nude mice were obtained from Harlan. The following recombinant human growth factors were gifts: HB-EGF and FGF2 from Scios Nova
Inc. and IGF-1 and VEGF-A from Genentech.
GPC1-knockout mice were produced by targeted mutagenesis in embryonic stem cells and maintained by backcrossing for more than 9 generations onto a CD-1 background prior to establishment of a homozygous
null colony. The targeting construct directed the deletion of a large portion of the first exon of the GPC1 gene, removing both the translational
start site and the signal peptide, and yielded homozygous animals in which
GPC1 mRNA is greatly reduced and GPC1 protein is undetectable. Homozygotes are viable and fertile.
Stable transfection. The GPC1 antisense construct was prepared by RTPCR amplification of human placenta cDNA, as described previously (11).
Stable transfection of GPC1-AS-1751 into PANC-1 cells was performed by
using the lipofectamine method (12), and single clones were isolated after
3-4 weeks. After expansion, cells from each individual clone were screened
96

The Journal of Clinical Investigation

for expression of GPC1 sense and antisense mRNA by northern blot analysis. Parental PANC-1 cells also were transfected with an empty expression
vector carrying the neomycin-resistance gene as a control. Positive clones
were routinely grown in selection medium.
Cell culture and growth assay. PANC-1 human pancreatic cancer cells were
grown in DMEM supplemented with 6% FBS (complete medium). T3M4
cells were grown in RPMI 1640 supplemented with 7% FBS. COS-7 cells
were grown in DMEM supplemented with 10% FBS. Murine B16-F10 melanoma cells were grown in RPMI 1640 supplemented with 5% FBS and
5 μM β-mercaptonethanol. All media were supplemented with 100 U/ml
penicillin and 100 μg/ml streptomycin. Medium for the melanoma cells
also contained amphotericin B (2.5 μg/ml). All cells were cultured at 37°C
in humidified air with 5% CO2.
Anchorage-dependent growth was assessed by cell counting with a hemacytometer, after plating 2.0 × 104 cells/well in 6-well plates and incubating
in complete medium. Cell doubling times were then calculated. Anchorage-independent growth was assessed by double-layer soft agar assay, as
previously reported (48). Briefly, 3.0 × 103 viable cells were suspended in
complete medium containing 0.3% agar and seeded in triplicate in 6-well
plates onto a base layer of complete medium containing 0.5% agar. Complete medium (1 ml) containing 0.3% agar was added every 5 days.
To assess the mitogenic effects of growth factors, cells were plated in 1 ml
of serum-free DMEM containing 0.1% BSA, 5 μg/ml transferrin, 5 ng/ml
sodium selenite, antibiotics, and 0.3% agar in the absence or presence of
growth factors. EGF, FGF-2, HB-EGF, or IGF-I, each a concentration of
1 nM, were added every 4 days. After 14 days, colonies consisting of more
than 10 cells were counted by microscopy using an Inverted Diaphot 300
microscope (Nikon Inc.).
Generation of GPC1-knockout mice on an athymic background. The nude
and GPC1 loci are on separate chromosomes, making it straightforward
to generate mice that are homozygous for both. Briefly, GPC1 –/– and
GPC1+/+ animals were crossed with nu/nu and nu/+ animals to yield
GPC1+/–nu/+ F1 hybrids. These were bred inter se, to yield an F2 generation of nu/nu and nu/+ animals from which only those that were GPC1+/+
and GPC1–/– were kept. Twenty one of each of these groups were bred
inter se (avoiding brother-sister matings) to yield offspring of which only
those that were GPC1+/+ nu/nu and GPC1–/– nu/nu were kept, and these
F3 mice were used for experiments.
In vivo tumorigenicity assays and tissue preparation. To assess the effects of
GPC1 suppression on tumorigenicity, 1 × 106 sham-transfected or GAS

Figure 12
Effect of endogenous GPC1 levels on pulmonary metastasis of
murine melanoma cells. Exponentially growing (1 × 10 5) murine
B16-F10 melanoma cells were injected into the lateral vein of mice.
Pulmonary metastases were counted 20–25 days later. Data are
means ± SEM from 16 WT mice and 20 GPC1-null mice. *P < 0.006
compared with WT.
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Table 3
Effects of host-derived GPC1 on T3M4 metastasis
Mouse
Mice with tumor
Tumor volume (mm3)
Lymph node metastasis (no.)
Liver metastasis (no.)
Spleen metastasis (no.)
Microvessel density (% area)

WT

GPC1–/–

7/7
1,088 ± 289
7
6
7
2.9 ± 0.6

8/8
1,115 ± 447
0
0
0
1.4 ± 0.3A

T3M4 cells (2 × 105/site) were injected into the pancreas of WT nude
and GPC1-null nude mice, using 28-gauge needles. Four weeks later,
the volumes of the intrapancreatic tumors and the extent of metastatic
involvement were determined. Tumor volumes are means ± SEM of
measurements from 7 WT mice and 8 GPC1-null mice. Calculation of
microvessel area was performed as described in Methods. AP < 0.04
when compared with WT. Tumor volumes were similar in both groups
of mice. Statistical analysis was not carried out with respect to lymph
node involvement.

PANC-1 cells were injected subcutaneously into the flank region on one
side of a 4- to 6-week-old, female athymic (nude) mouse. The animals were
monitored for tumor formation every week and killed 8–15 weeks after
injection when the tumor diameter became 15 mm3. Tumor volume was
calculated as π/4 × width × height × length of the tumor, as previously
reported (48). Tumors were rapidly excised and divided into 3 fragments.
One tumor fragment was snap frozen in liquid nitrogen and stored at
–80°C. Another tumor fragment was embedded in OCT, frozen in liquid
nitrogen, and stored at –80°C for subsequent staining with anti-CD31
antibody (49). The third tumor fragment was fixed in formalin and embedded in paraffin for subsequent immunohistochemical staining.
For orthotopic inoculation of cancer cells, parental, sham-transfected
or GPC1 antisense-transfected PANC-1 cells (2 × 106) or parental T3M4
cells (2 × 105) were injected into the pancreas of 4- to 6-week-old female
athymic (nude) mice, using 28-gauge needles. Passage through this size
needle did not alter cellular viability and was not associated with leaking
from the injection site. At autopsy, the size of the intrapancreatic tumors
was measured and the tumor volume was determined as above (48), and
the number of metastatic lymph nodes was counted.
To perform studies with melanoma cells, exponentially growing murine
B16-F10 melanoma cells were harvested, washed, and resuspended in PBS.
Cells (100,000 in 250 μl of PBS) were injected into the lateral vein of the
mice. Mice were watched daily starting at day 14 after injection, and in 4
separate experiments using 4 to 5 mice per group, they began to appear
ill due to lung tumor burden 20–25 days following the injection. All the
mice in each experiment were sacrificed on the same day, as soon as they
appeared ill. The lungs were immediately removed and placed briefly in
PBS containing 3% hydrogen peroxide and 10% buffered formalin. The
number of pulmonary metastases was then counted. All studies with mice
were approved by Dartmouth Medical School Institutional Animal Care
and Use Committee.
Immunoblotting. Sham- and GAS cells and tissue samples were lysed in
lysis buffer containing 50 μg/ml aprotinin, 10 μg/ml leupeptin, 10 μg/ml
pepstatin A, 10 μg/ml benzamidine, and 1 mM PMSF (50). GPC1 generally appears on immunoblots as broad, faintly stained high-molecularweight smears, in part due to poor binding of proteoglycans to blotting
membranes (11). However, after digestion with heparitinase (to remove
HSs) or heparitinase in conjunction with chondroitinaseABC (to also
remove chondroitin sulfates), GPC1 migrates as a relatively distinct
band on SDS-PAGE. Therefore, when performing immunoblotting for
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GPC1, cell lysates were first incubated in the absence or presence of these
enzymes for 3 h at 37°C and subjected to SDS-PAGE and electrotransferred to Immobilon-P membrane. To study conditioned media, shamtransfected and GAS cells were incubated with PI-PLC and heparitinase
for 1 h. Following concentration in a Microcon YM-10, media proteins
were subjected to SDS-PAGE and electrotransferred to ImmobilonP PVDF membranes. After blocking, membranes were blotted with an
affinity-purified rabbit anti-human GPC1 antibody and with a secondary
horseradish peroxidase-conjugated antibody. Bound antibody was visualized using enhanced chemiluminescence.
To assess the consequences of altered GPC1 levels on MAPK activation,
membranes were stripped for 30 min at 50°C in buffer containing 2%
SDS, 62.5 mM Tris (pH 6.7), and 100 mM 2-mercaptoethanol and blotted with an anti–phospho-ERK (anti–active MAPK) antibody. To confirm
equal loading of lanes, membranes were stripped again and blotted with
an anti-ERK2 antibody.
Immunohistochemistry of paraffin-embedded and frozen tissues. Paraffinembedded tumor tissues were sectioned (5 μm thick), mounted on polyl-lysine-coated glass slides, and allowed to dry overnight at 23°C. These
sections were used for detection of PCNA and apoptosis by the ApopTag
TUNEL assay, as previously reported (50, 51).
PCNA, angiopoietin-1, angiopoietin-2, and Tie2 immunostaining was
performed using the streptavidin-peroxidase technique (VECTASTAIN
ABC Kit; Vector Labs). After deparaffinization, antigen retrieval was performed by heating in a microwave oven (95°C) for 5 min in 10 mM citrate
buffer at pH 6.0 (PCNA) or by using a 2100-Retriever (PickCell Laboratories) and Antigen Unmasking Solution (angiopoietin-1, angiopoietin-2,
and Tie2). Sections were then incubated for 10 min with 3% hydrogen
peroxide to block endogenous peroxidase activity, for 30 min at 23°C with
5% normal goat serum, and overnight at 4°C with a monoclonal antiPCNA antibody (2 μg/ml). Bound antibody was detected with biotinylated
anti-mouse IgG and VECTASTAIN ABC Reagent (Vector Labs) complex,
using diaminobenzidine tetrahydrochloride (DAB) as the substrate (50).
Some sections were incubated without primary antibodies and did not
yield positive immunoreactivity.
Two types of immunostaining procedures were performed to assess
microvessel density. First, for tumor tissues frozen in OCT, sections
(5 μm thick) were mounted on poly-l-lysine–coated glass slides and airdried overnight at 23°C (49, 50). Frozen tissue sections were fixed in acetone for 5 min, and endogenous peroxidase activity was blocked by incubation for 10 min with 3% hydrogen peroxide. Samples were then incubated

Figure 13
Effects of endogenous GPC1 levels on endothelial cell proliferation.
Endothelial cells isolated from WT or GPC1-null mice were plated in
triplicate on fibronectin-coated 96-well plates, serum-starved overnight, and incubated for 48 h in the presence of 0.5% BSA (control)
or 50 ng/ml VEGF-A. Data are means ± SEM. *P < 0.05 compared
with control.
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Figure 14
Schematic representation of the role of
GPC1 in tumor angiogenesis and metastasis.
Endothelial cells expressing VEGF receptors,
Tie2, and GPC1 (iv) are shown interacting with
cancer cell–derived VEGF-A, angiopoietin-1,
and angiopoietin-2 (i), cancer cell–derived
GPC1 acting in trans (ii), shed GPC1 (iii), and
fibroblast-derived GPC1 (v). Thus host- and
tumor-derived GPC1 combine to contribute to
tumor angiogenesis.

for 30 min at 23°C with 5% normal rabbit serum in PBS and overnight
at 4°C with monoclonal anti-CD31 antibody (1 μg/ml). Bound antibody
was detected with biotinylated rabbit anti-rat IgG secondary antibody and
streptavidin-peroxidase complex, using DAB as the substrate. Second, for
paraffin embedded tissues, endothelial cells were detected with the anti–VE
cadherin antibody. Sections in both of the above procedures were counterstained with Mayer's hematoxylin.
To identify individual apoptotic cells in tissue sections, the TUNEL
method consisting of the ApopTag in situ apoptosis detection kit (BD
Pharmingen) that specifically recognizes 3′-OH DNA ends generated by
DNA fragmentation was used according to the manufacturer’s directions,
as previously described (51). Briefly, deparaffinized and proteinase K–
digested tissue sections were incubated for 60 min at 37°C with terminal
deoxynucleotidyl transferase (TdT) enzyme and digoxigenin-dUTP after
blocking of endogenous peroxidase activity. Digoxigenin residues catalytically bound to the DNA 3′-OH ends by TdT were detected by antidigoxigenin antibodies conjugated with peroxidase, using DAB as the substrate,
followed by counterstaining with methyl green. Omission of TdT enzyme
did not yield any immunoreactivity.
To perform quantitative morphometry, the stained slides were analyzed
with Image-Pro Plus (Media Cybernetics), as previously reported (50). Three
fields at ×100 magnification were chosen randomly from each tumor for
CD31 staining, and 5 fields at ×200 magnification were analyzed following
TUNEL and PCNA staining.
Anti-peptide antibodies. Anti-GPC1 antibodies were generated by Genemed
Synthesis Inc., using a peptide corresponding to amino acid residues 343 to
360 of human GPC1 (CGNPKVNPQGPGPEEKRR) that was synthesized
and conjugated to keyhole limpet hemocyanin as previously reported (52).
Following purification over Sephadex G-25 column, the peptide conjugate
was injected intradermally into rabbits, using complete Freund’s adjuvant.
For affinity purification of the antibody, the purified peptide immunogen (10 mg) was coupled to SulfoLink Coupling Gel (Pierce Biotechnology)
according to the manufacturer’s protocol. The anti-GPC1 antibody was
purified using a 0.5-ml column equilibrated with PBS. The antibody was
eluted with 50 mM glycine/0.15 M NaCl (pH 2.5) and neutralized with 1 M
Tris buffer. The fractions with the highest reading at 280 OD were pooled
(final pH 8.5), and the antibody was dialyzed overnight in PBS.
COS-7 cells were transiently transfected using lipofectamine with a
construct encoding GPC1 fused to alkaline phosphatase, termed “APT6GPC1” (13). The medium was collected 3–5 days after transfection, filtered,
and stored at –80°C until use. An antigen-capture ELISA was performed to
determine the affinity of the purified antibody, using 96-well Nunc Immunoplates (Nunc) that were coated with Protein A (50 μg/ml) for 1 h at
98
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37°C. After washing with PBS, medium from the APT6-GPC1–transfected
COS-7 cells that had been heat inactivated for 10 min (65°C) was added to
the plates, and incubation was continued for 2 h at 37°C. After washing,
p-nitrophenol phosphate (in 2 M diethanolamine, pH 8.8, 1 mg/ml BSA,
and 1 mM MgCl2) was added to each well. Incubations were continued
at 37°C for 20 min and reactions terminated by adding 0.5 M NaPO4
(pH 8.0). OD readings were performed on a microplate reader at 405 nm.
Endothelial cell isolation and proliferation assay. Primary endothelial cells were
isolated from adult mouse livers following mechanical mincing and collagenase (2 mg/ml) digestion for 30 min at 37°C. Cells were isolated by incubating for 30 min at 23°C with magnetic Dynabeads (Invitrogen) labeled with
anti-CD31 antibodies and using a magnetic separator (53). Cells were then
incubated in DMEM supplemented with 20% FBS, penicillin/streptomycin
(100 U/ml), heparin (100 μg/ml), endothelial cell growth factor (100 μg/
ml), 1× nonessential amino acids, 2 mM l-glutamine, 1× sodium pyruvate,
gentamicin (58 μg/ml), and amphotericin B (25 ng/ml), termed “complete
endothelium medium.” To assess the effects of VEGF-A on endothelial cell
proliferation, cells from passage 1 or 2 were plated for 4 h in 96-well cell
culture plates coated with fibronectin (5 μg/ml) at a density of 4,000 cells
per well. The medium was then replaced with fresh complete endothelium
medium containing 2% FBS and 0.5% BSA. Cells were incubated at 37°C for
48 h in the absence or presence of 50 ng/ml VEGF-A, prior to the addition
of One Solution reagent (Promega) for 2 h. Optical density was then determined at 490 nm on a Molecular Devices microplate reader.
Preparation of mouse embryonic fibroblasts. Primary MEFs were isolated from
13.5-day-old embryos by trypsin digestion. The cells were resuspended in
DMEM containing 8% FBS, 100 U/ml penicillin/streptomycin, and 25 ng/ml
amphotericin B. Following plating on tissue culture plates and incubation
at 37°C with 5% CO2, cells were collected for RNA isolation.
Quantitative real-time PCR. To assess expression of proangiogenic factors
in the tumors, RNA extraction, RT-PCR, and first-strand cDNA synthesis for quantitative real-time PCR analysis (Q-PCR) were carried out as
described previously (54, 55). Target gene sequences were from the National
Center for Biotechnology Information GenBank databases. Q-PCR was
performed using an ABI PRISM 7300 sequence detection system (Applied
Biosystems). RNA expression was calculated based on a relative standard
curve representing 4-fold dilutions of human cDNA. Q-PCR data were
expressed as a relative quantity based on the ratio of the fluorescent change
observed with the target gene to the fluorescent change observed with 18S
ribosomal subunit. Hepatic endothelial cell and MEF RNA samples were
isolated with the Qiagen RNeasy kit following the manufacturer’s directions, and Q-PCR was performed as described above, using the Applied
Biosystems TaqMan Assay with prevalidated murine probes and primer
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sets. A dilution series was carried out for each gene, and the 18S ribosomal
subunit was used as an internal control.
Statistics. Unless otherwise indicated, Student’s t test was used for statistical analysis, with P < 0.05 defined as significant.
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